Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
06 Septiembre 2022 - 3:05PM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, today announced that Gail McIntyre, Ph.D., DABT, Chief
Executive Officer and Rudy Howard, Chief Financial Officer will
participate in the H.C. Wainwright 24th Annual Global Investment
Conference taking place September 12-14, 2022 at the Lotte New York
Palace Hotel, New York, N.Y.
The Company’s presentation will be available for viewing on
September 12, 2022, at 7:00 am ET. An archived replay of the
webcast will be available for 90 days following the webcast on
the Events & Presentations
page of www.aravive.com. Aravive will also participate in
one-on-one meetings at the conference.
About AraviveAravive, Inc. is a late
clinical-stage oncology company developing targeted therapeutics to
treat metastatic disease. Our lead product candidate, batiraxcept
(formerly AVB-500), is an ultra-high affinity decoy protein that
binds to GAS6, the sole ligand that activates AXL, thereby
inhibiting metastasis and tumor growth, and restoring sensitivity
to anti-cancer agents. Batiraxcept has been granted Fast Track
Designation by the U.S. FDA and Orphan Drug Designation by the
European Commission in platinum-resistant recurrent ovarian cancer.
Batiraxcept is in an active registrational Phase 3 trial in
platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial
in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2
trial in pancreatic adenocarcinoma (NCT04983407). The Company is
based in Houston, Texas and received a Product Development Award
from the Cancer Prevention & Research Institute of Texas
(CPRIT) in 2016. Additional information at
www.aravive.com.
Contact:Luke HeagleReal Chemistry(910)
619-5764ir@aravive.com
Aravive (NASDAQ:ARAV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aravive (NASDAQ:ARAV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024